問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Shin Kong Memorial Wu Ho-Su Hospital (在職)

Division of Ophthalmology

更新時間：2023-09-19

鄭成國
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鄭成國

List

14Cases

2017-09-01 - 2018-09-06

Phase III

SAPPHIRE: A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion

  • Condition/Disease

    subjects with retinal vein occlusion

  • Test Drug

    CLS-TA

Participate Sites
5Sites

Terminated4Sites

2019-08-01 - 2022-03-31

Phase III

A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration (TALON)

  • Condition/Disease

    neovascular age-related macular degeneration (TALON)

  • Test Drug

    Brolucizumab (RTH258)

Participate Sites
4Sites

Recruiting4Sites

2021-01-07 - 2023-06-08

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2013-09-03 - 2020-06-30

Phase I/II

A Phase I/II trial of TLC399 (ProDex) in Patients with Macular Edema due to Retinal Vein Occlusion (RVO): An Open-label, Sequential Dose Escalation Phase I Part to Determine Maximum Tolerated Dose (MTD) and Dose Limiting Toxicities (DLTs) Followed by a Single-masked, Randomized Part to Evaluate Efficacy and Tolerability

  • Condition/Disease

    Macular Edema due to Retinal Vein Occlusion (RVO)

  • Test Drug

    TLC399 (ProDex)

Participate Sites
7Sites

Terminated7Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB